Compass Pathways通过授权令筹集2亿美元

2026-02-26 20:37

Compass Pathways (CMPS) said holders exercised 35,059,448 warrants issued on January 13, 2025, generating about $200M in proceeds for the company.
As a result, Compass is issuing 15,160,619 American Depositary Shares (ADSs) and, in lieu of ADSs for certain institutional investors, pre-funded warrants to purchase up to 19,898,829 ADSs.
Compass Pathways currently intends to use the proceeds from these warrant exercises, together with its existing cash and cash equivalents, to fund ongoing COMP005 and COMP006 Phase 3 trials, its Phase 2b/3 trial of COMP360 in PTSD, acceleration of its commercial readiness activities, and for working capital and general corporate purposes.
The net proceeds from these warrant exercises, along with the net proceeds of ~$141M from a recent public offering, and its existing cash and cash equivalents, are expected to be sufficient to fund operating expenses and capital expenditure requirements into 2028.
CMPS shares fell 1% premarket at $7.36.

More on COMPASS Pathways ADS